Macogenic G2 for extracorporeal photopheresis
Extracorporeal Photopheresis (ECP) has been recognised by the scientific community as a therapeutic option to treat various disorders, such as:
. Cutaneous T-cell lymphoma (Sezary syndrome)
. GVHD (acute and chronic)
. Solid organ transplant rejection
Macopharma has developed a complete product range for the off-line extracorporeal photpheresis technique.
Extracorporeal photopheresis (ECP) is based on the exposure of peripheral blood mononuclear cells to the photosensitizing agent (8-methoxypsoralen or 8-MOP) and UVA irradiation.
Mononuclear cells are harvested by an apheresis device usually and reinfused to the patient after cell irradiation.
Ref. XUV8501Q – Bag for U.V. treatment of blood cells
- Nominal volume: 3 L
- Connections: 1 spike, 1 injection site, 1 outlet port
Ref. CSL1800XA – Methoxsalen (8-MOP) MACO PHARMA 20 micrograms/mL, solution
Produit Thérapeutique Annexe (PTA)
Marketing Authorisation in France
AMM PTA N°: TA 07.10.109
- Volume: 5 mL
Ref. 9MG2000 – Macogenic G2
- Weight: 67 kg
- Dimensions: 87 cm (width) x 64 cm (depth) x 38 cm (height)